http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-1151663-A
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_03721e344a72026d125291e6c56c1be6 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F15-0093 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F9-3808 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F9-38 |
filingDate | 1980-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 1983-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cac33f07b4cfa0f471d7bf334d8c4190 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8f2103940d0e90162a83dc356a223834 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6c16c800bcc7e0098ae9e26a12463846 |
publicationDate | 1983-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CA-1151663-A |
titleOfInvention | (n-phosphonacetyl-l-aspartato) (1,2-diaminocyclohexane)-platinum(ii) or alkali metal salt |
abstract | ABSTRACT OF THE DISCLOSURE where X is Na+, K+, Li+, NH4 or H (N-phosphonacetyl-L-aspartato) (1,2-diaminocyclohexane)platinum(II) or alkali metal or ammonium salt thereof has shown antitumor activity in animals such as activity against murine leukemia L1210. Additionally, this agent is used against B-16 and Colon 38 tumors and also Ehrlich ascites tumor. It is effective in dosages of 5-60 mg/kg of body weight and is potentiated in a treatment with cyclophosphamide (CY) (50 mg/kg of body weight) to which may be added hydroxyurea (HU) (1000-1500 mg/kg of body weight). In binary treat-ment with cis-dichlorodiamineplatinum(II) (or cisplatin) the preferred ratio of the present compound to cisplatin is about 10:1 with a range of about 10:1 to 1:10 in mg/kg of body weight. The present platinum compound may be pre-pared by reacting the known L-aspartic acid, N-(phosphonacetyl-)disodium salt (PALA; NSC-224131), with dinitrato(1,2-diaminocyclohexane)platinum(II) (NSC-239851). This compound N-phosphonacetyl-L-aspartato (1,2-diaminocyclohexane) platinum (II) may be combined in multiple drug regimen with substantially improved yield cures over the parent compounds. For example, the compound denoted Pt-268 may be combined in a dual regimen with cyclophosphamide (CY), hydroxyurea (HU), and cisplatin. |
priorityDate | 1979-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 805.